Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19175378 | ENCAPSULATED RESVERATROL (RSV) NANOPARTICLES | April 2025 | October 2025 | Allow | 6 | 1 | 0 | No | No |
| 19175330 | ENCAPSULATED RESVERATROL (RSV) NANOPARTICLES | April 2025 | December 2025 | Allow | 8 | 1 | 0 | No | No |
| 19173931 | ENCAPSULATED RESVERATROL (RSV) NANOPARTICLES | April 2025 | September 2025 | Allow | 6 | 1 | 0 | No | No |
| 19174154 | ENCAPSULATED RESVERATROL (RSV) NANOPARTICLES | April 2025 | January 2026 | Allow | 9 | 1 | 0 | No | No |
| 19004832 | ENCAPSULATED RESVERATROL (RSV) NANOPARTICLES | December 2024 | November 2025 | Allow | 11 | 1 | 1 | No | No |
| 18758839 | STABLE NIMODIPINE PARENTERAL FORMULATION | June 2024 | March 2025 | Allow | 9 | 1 | 1 | No | No |
| 18658056 | LIQUID CRYSTALLINE DOSAGE FORM FOR ADMINISTERING A STATIN | May 2024 | September 2025 | Allow | 16 | 2 | 0 | No | No |
| 18643086 | FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | April 2024 | May 2025 | Allow | 13 | 2 | 0 | No | No |
| 18641848 | 4-[4,5-BIS(4-BROMOPHENYL)-1-HEXYL-1H-IMIDAZOL-2-YL]ISOQUINOLIN-3-OL AS AN ANTIMICROBIAL COMPOUND | April 2024 | October 2024 | Allow | 6 | 1 | 0 | No | No |
| 18641845 | 4-[4,5-BIS(4-BROMOPHENYL)-1-HEXYL-1H-IMIDAZOL-2-YL]ISOQUINOLIN-3-OL AS AN ANTIMICROBIAL COMPOUND | April 2024 | October 2024 | Allow | 6 | 1 | 0 | No | No |
| 18629364 | Pharmaceutical Composition And Method For Treating Seizure Disorders | April 2024 | February 2026 | Abandon | 23 | 2 | 1 | No | No |
| 18626675 | METHODS FOR IMPROVING RESPIRATORY SYSTEM HEALTH AND INCREASING THE CONCENTRATION OF HYPOTHIOCYANATE ION IN VERTEBRATE LUNGS | April 2024 | July 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18616858 | Cannabinoid Pouch | March 2024 | February 2025 | Allow | 11 | 1 | 0 | No | No |
| 18616577 | 2-(BENZO[D]THIAZOL-2-YL)-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | March 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18616603 | 2-(BENZO[D]THIAZOL-2-YL)-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | March 2024 | August 2024 | Allow | 5 | 1 | 0 | No | No |
| 18437368 | CAPSULE FORMULATIONS | February 2024 | April 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18429916 | METHODS OF PEST CONTROL IN SOYBEAN | February 2024 | June 2025 | Allow | 17 | 1 | 0 | No | No |
| 18426211 | 9-(6-FLOURO-2-HYDROXYPYRIDIN-3-YL)-10-(2-HYDROXYETHYL)-3,6-DIPHENYL-3,4,6,7,9,10-HEXAHYDROACRIDINE1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUND | January 2024 | September 2024 | Allow | 7 | 1 | 0 | No | No |
| 18426092 | 9-(6-FLOURO-2-HYDROXYPYRIDIN-3-YL)-10-(2-HYDROXYETHYL)-3,6-DIPHENYL-3,4,6,7,9,10-HEXAHYDROACRIDINE1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUND | January 2024 | August 2024 | Allow | 7 | 1 | 0 | No | No |
| 18421535 | 2-[(1,3-BENZOTHIAZOL-2-YL)IMINO]-5,5-DIPHENYLIMIDAZOLIDIN-4-ONE AS AN ANTIMICROBIAL COMPOUND | January 2024 | September 2024 | Allow | 8 | 1 | 1 | No | No |
| 18396828 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION | December 2023 | February 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18538502 | AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOF | December 2023 | March 2025 | Allow | 15 | 1 | 0 | No | No |
| 18514306 | MODIFIED WOUND DRESSINGS | November 2023 | November 2024 | Allow | 12 | 1 | 0 | No | No |
| 18387755 | 4-[4,5-BIS(4-BROMOPHENYL)-1-HEXYL-1H-IMIDAZOL-2-YL]ISOQUINOLIN-3-OL AS AN ANTIMICROBIAL COMPOUND | November 2023 | April 2024 | Allow | 5 | 1 | 1 | No | No |
| 18387202 | 9-(6-FLOURO-2-HYDROXYOUINOLIN-3-YL)-10-(2-HYDROXYETHYL)-3,6-DIPHENYL-3,4,6,7,9,10-HEXHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUND | November 2023 | January 2024 | Allow | 3 | 1 | 0 | No | No |
| 18502663 | ORAL CANNABINOID PRODUCT WITH LIPID COMPONENT | November 2023 | April 2025 | Allow | 17 | 1 | 1 | No | No |
| 18488231 | CROSS-LINKED PROTEIN FOAMS AND METHODS OF USING THEREOF A POLYVALENT CELLULAR SCAFFOLD | October 2023 | December 2024 | Allow | 14 | 1 | 0 | No | No |
| 18487995 | 2-[(1,3-BENZOTHIAZOL-2-YL)IMINO]-5,5-DIPHENYLIMIDAZOLIDIN-4-ONE AS AN ANTIMICROBIAL COMPOUND | October 2023 | November 2024 | Abandon | 13 | 3 | 1 | No | No |
| 18379966 | 2-(BENZO[D]THIAZOL-2-YL)-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18379398 | SYSTEM AND METHOD FOR PRIMING EYE COSMETICS | October 2023 | December 2025 | Allow | 26 | 1 | 0 | No | No |
| 18485929 | VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODS | October 2023 | March 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18378009 | Synthesis and Antimicrobial Uses of Dinuclear Silver(I) Pyrazolates | October 2023 | January 2025 | Allow | 15 | 1 | 0 | No | No |
| 18474798 | Perfume Compositions | September 2023 | March 2025 | Abandon | 18 | 1 | 1 | No | No |
| 18474782 | Perfume Compositions | September 2023 | December 2024 | Allow | 14 | 1 | 1 | No | No |
| 18371043 | VARIABLE-SIZE HYDROPHOBICALLY-MODIFIED POLYMERS | September 2023 | July 2025 | Abandon | 22 | 2 | 1 | No | No |
| 18368097 | PHYSIOLOGICALLY ACTIVE SUBSTANCE CARRIER | September 2023 | July 2024 | Allow | 10 | 1 | 0 | No | No |
| 18243299 | NON-SURFACTANT TYPE OIL-WATER DISPERSION COMPOSITION, NON-SURFACTANT TYPE WATER-OIL DISPERSION COMPOSITION, AND MANUFACTURING METHODS FOR BOTH COMPOSITIONS | September 2023 | October 2024 | Allow | 13 | 1 | 1 | No | No |
| 18548181 | APPLICATION OF BMSC-EXOS IN TREATING PD | August 2023 | December 2025 | Allow | 27 | 1 | 0 | No | No |
| 18278474 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | August 2023 | March 2026 | Abandon | 30 | 0 | 1 | No | No |
| 18236466 | PERSONAL LUBRICANTS COMPRISING LAMBDA-CARRAGEENAN | August 2023 | May 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18235855 | PRESERVATION OF PERSONAL CARE COMPOSITIONS | August 2023 | January 2025 | Allow | 17 | 1 | 1 | No | No |
| 18359317 | Pharmaceutical Formulation | July 2023 | December 2025 | Abandon | 29 | 2 | 1 | No | No |
| 18270763 | ULTRAVIOLET LIGHT-BLOCKING COMPOSITION COMPRISING CENTIPEDE GRASS EXTRACT AND COSMETIC COMPOSITION COMPRISING SAME | July 2023 | February 2026 | Allow | 32 | 1 | 0 | No | No |
| 18341541 | METHOD FOR DEPOT CREATION DURING TRANSDERMAL DRUG DELIVERY | June 2023 | December 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18337974 | METHODS FOR TREATING ALZHEIMER'S DISEASE WITH DONEPEZIL TRANSDERMAL SYSTEM | June 2023 | March 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18206141 | NOVEL NANOEMULSIONS COMPRISING FATTY ACID AND N-ACYL DERIVATIVES OF AMINO ACID SALT | June 2023 | March 2025 | Allow | 21 | 2 | 1 | No | Yes |
| 18329992 | METHODS AND COMPOSITIONS FOR TREATING DIABETIC FOOT ULCERS | June 2023 | January 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18324472 | METHODS OF PEST CONTROL IN SOYBEAN | May 2023 | March 2024 | Abandon | 9 | 1 | 0 | No | No |
| 18319794 | OPHTHALMIC EMULSION | May 2023 | December 2024 | Allow | 19 | 1 | 1 | No | No |
| 18195920 | ANTIDIABETIC PHARMACEUTICAL COMPOSITIONS | May 2023 | November 2025 | Allow | 30 | 1 | 1 | No | No |
| 18309804 | SLOW RELEASE CANNABINOIDS AND PRODUCTS THEREOF | April 2023 | March 2024 | Allow | 11 | 2 | 0 | No | No |
| 18303387 | DRUG DELIVERY SYSTEM FOR TREATING DISEASE | April 2023 | April 2025 | Allow | 23 | 2 | 1 | No | No |
| 18128922 | PHARMACEUTICAL FORMULATIONS | March 2023 | February 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18124129 | Oral Pharmaceutical Composition, Method for Fabricating Thereof, and Kit for Treating Cancer | March 2023 | February 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18122208 | VARIABLE-SIZE HYDROPHOBICALLY-MODIFIED POLYMERS | March 2023 | November 2025 | Allow | 32 | 4 | 1 | Yes | No |
| 18179405 | DEFINED DOSE CANNABIS PUCK | March 2023 | December 2025 | Abandon | 34 | 2 | 1 | No | No |
| 18043743 | PALATABLE FORMULATIONS | March 2023 | October 2025 | Allow | 31 | 1 | 1 | No | No |
| 18022638 | LOW HYGROSCOPICITY ACTIVE POWDER COMPOSITIONS | February 2023 | December 2025 | Allow | 34 | 1 | 1 | No | No |
| 18169553 | METHODS FOR TREATING OCULAR DEMODEX USING SPINOSAD FORMULATIONS | February 2023 | February 2026 | Allow | 36 | 1 | 0 | No | No |
| 18109349 | Nutritional Supplement | February 2023 | September 2023 | Allow | 7 | 0 | 0 | No | No |
| 18109568 | Formulations for the Delivery of Autophagy Stimulating Trehalose | February 2023 | June 2024 | Allow | 16 | 1 | 1 | No | No |
| 18094080 | ASCORBATE IN THE PREVENTION OF STATIN INDUCED VASCULAR CALCIFICATION | January 2023 | October 2023 | Allow | 10 | 1 | 1 | No | No |
| 18090128 | FRAGRANCE COMPOSITIONS CONTAINING NORBORNENE DERIVATIVES FOR PERSONAL CARE PRODUCTS | December 2022 | September 2023 | Allow | 9 | 0 | 0 | No | No |
| 18089134 | Halogenated Xanthene-Containing Topical Anti-Gram-Positive Bacterial Ophthalmic Composition and Method | December 2022 | February 2026 | Allow | 38 | 2 | 1 | No | No |
| 18088564 | Solid Phase Carrier for Vapor Delivery | December 2022 | February 2026 | Abandon | 38 | 0 | 1 | No | No |
| 18145334 | NANOCRYSTAL MICROPARTICLES OF POORLY SOLUBLE DRUGS AND METHODS OF PRODUCTION AND USE THEREOF | December 2022 | January 2026 | Allow | 37 | 1 | 1 | No | No |
| 18012410 | SMALL MOLECULAR DRUG-LOADED POLYMER VESICLE, PREPARATION METHOD THEREFOR AND USE THEREOF | December 2022 | October 2025 | Allow | 34 | 1 | 1 | No | No |
| 18085720 | PERSONAL LUBRICANTS COMPRISING LAMBDA-CARRAGEENAN | December 2022 | March 2024 | Allow | 15 | 1 | 0 | No | No |
| 18011796 | CONDOMS LUBRICATED WITH ANTIVIRAL LUBRICIOUS COMPOSITIONS CONTAINING LAMBDA-CARRAGEENAN | December 2022 | March 2024 | Allow | 15 | 1 | 0 | No | No |
| 18062351 | Activated Cannabinoid Controlled Release Compound Tablet and Method of Forming The Same | December 2022 | May 2024 | Allow | 17 | 1 | 1 | No | No |
| 18057554 | Topical Therapy of Skin Fibrosis and Melanoma | November 2022 | May 2025 | Abandon | 30 | 4 | 1 | No | No |
| 17999191 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NON-SMALL CELL LUNG CANCER ASSOCIATED WITH RON MUTANTATION, AND METHOD USING SAME | November 2022 | January 2026 | Abandon | 38 | 1 | 0 | No | No |
| 17988412 | Cannabinoid Pouch | November 2022 | December 2023 | Allow | 13 | 1 | 0 | No | No |
| 17985636 | COMBINATIONS OF NANOPARTICLE-ENCAPSULATED CARGO ENTITIES AND METHODS FOR MAKING AND USING SAME | November 2022 | September 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17985748 | METHOD AND KIT FOR PROVIDING A CUSTOMIZABLE NAIL-BITING AND FINGER SUCKING PREVENTION TREATMENT | November 2022 | May 2025 | Allow | 30 | 4 | 0 | No | No |
| 18054055 | LIQUID CRYSTALLINE DOSAGE FORM FOR ADMINISTERING A STATIN | November 2022 | June 2024 | Abandon | 19 | 2 | 0 | No | No |
| 17982950 | WATER-SOLUBLE MICROENCAPSULATED CANNABINOID EXTRACT POWDER AND METHOD OF MAKING THE SAME | November 2022 | February 2024 | Abandon | 16 | 1 | 0 | No | No |
| 17970632 | Aqueous Solution For Use In Cleaning Via Irradiation By Ultraviolet Rays And/Or Near-Ultraviolet Visible Light And/Or Light In 800-900 NM Near-Infrared Region, Dentifrice Including Said Solution, Dental Treatment Device, Toothbrush, And Tooth Cleaning Met | October 2022 | November 2023 | Allow | 13 | 1 | 0 | No | No |
| 17970639 | Aqueous Solution For Use In Cleaning Via Irradiation By Ultraviolet Rays And/Or Near-Ultraviolet Visible Light And/Or Light In 800-900 NM Near-Infrared Region, Dentifrice Including Said Solution, Dental Treatment Device, Toothbrush, And Tooth Cleaning Met | October 2022 | October 2023 | Allow | 12 | 1 | 0 | No | No |
| 17969905 | MALTO-DEXTRIN COMPOSITION WITH LOW DE VALUE AND LOW VISCOSITY AND METHOD FOR MAKING THE SAME | October 2022 | January 2026 | Abandon | 39 | 2 | 0 | No | No |
| 17967834 | PROCESSES FOR PRODUCING PARTICLES OF AT LEAST ONE POLYHYDROXYALKANOATE (PHA) | October 2022 | March 2024 | Abandon | 17 | 1 | 0 | No | No |
| 17963607 | INHALABLE IMATINIB FORMULATIONS, MANUFACTURE, AND USES THEREOF | October 2022 | March 2025 | Abandon | 29 | 2 | 0 | No | Yes |
| 17958876 | VOLATILE OILY COMPOSITION | October 2022 | August 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17935667 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION | September 2022 | September 2023 | Allow | 12 | 1 | 0 | No | No |
| 17934727 | Abiotic Anti-VEGF Nanoparticle | September 2022 | November 2023 | Allow | 14 | 1 | 0 | No | No |
| 17934056 | TRANSDERMAL CARRIER | September 2022 | December 2023 | Allow | 15 | 1 | 0 | No | No |
| 17912570 | NUTRITIONAL HEALTH SUPPLEMENTS | September 2022 | October 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17912660 | Additive for Detoxification | September 2022 | October 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17945221 | HERBICIDAL COMPOUNDS | September 2022 | April 2024 | Allow | 19 | 2 | 1 | No | No |
| 17929396 | FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | September 2022 | March 2024 | Allow | 19 | 2 | 0 | No | No |
| 17633317 | Skin Whitening Composition Containing Dihydro-5-Methylfuran-2(3h)-One Derivative | August 2022 | December 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17797022 | ORAL SUSPENSION WITH ANTIULCEROUS AND CHEMOPROTECTIVE EFFECT ON COLON CANCER AND PREPARATION METHOD THEREOF | August 2022 | February 2026 | Abandon | 43 | 1 | 1 | No | No |
| 17878947 | ACTIVE AGENT-CONTAINING ARTICLES | August 2022 | May 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17874818 | LIPID COMPOSITION FOR THE DELIVERY OF THERAPEUTIC CARGOS | July 2022 | December 2024 | Abandon | 28 | 3 | 1 | No | No |
| 17863884 | DRUG DELIVERY SYSTEM | July 2022 | January 2024 | Allow | 19 | 1 | 0 | No | No |
| 17863428 | SLOW RELEASE CANNABINOIDS AND PRODUCTS THEREOF | July 2022 | February 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 17861413 | Lanthanum Carbonate Hydroxide, Lanthanum Oxycarbonate and Methods of Their Manufacture and Use | July 2022 | December 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17861210 | CLEANSING PAD AND COMPOSITION FOR REDUCING TOXINS | July 2022 | May 2024 | Abandon | 22 | 1 | 1 | No | No |
| 17758554 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | July 2022 | July 2023 | Allow | 13 | 1 | 1 | Yes | No |
| 17790351 | MOLDED COMPOSITION FOR TOPICAL APPLICATION AND USES THEREOF | June 2022 | November 2025 | Abandon | 41 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SONG, JIANFENG.
With a 29.2% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 22.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SONG, JIANFENG works in Art Unit 1613 and has examined 770 patent applications in our dataset. With an allowance rate of 53.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 27 months.
Examiner SONG, JIANFENG's allowance rate of 53.8% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SONG, JIANFENG receive 2.27 office actions before reaching final disposition. This places the examiner in the 63% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by SONG, JIANFENG is 27 months. This places the examiner in the 71% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +39.4% benefit to allowance rate for applications examined by SONG, JIANFENG. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.2% of applications are subsequently allowed. This success rate is in the 32% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 19.3% of cases where such amendments are filed. This entry rate is in the 23% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 72.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 59% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 71.4% of appeals filed. This is in the 58% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 70.9% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.1% of allowed cases (in the 50% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.5% of allowed cases (in the 55% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.